Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents

Investigational New Drugs

Volumn 14, Issue 2, 1996, Pages 161-167

  Kelner, Michael J ^a,c   McMorris, Trevor C ^a   Estes, Leita ^a   Wang, Wen ^a   Samson, Kyra M ^a   Taetle, Raymond ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; HMAF; Illudin; Xenograft

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; HELICASE; ILLUDIN S; MITOMYCIN C; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; LUNG ADENOCARCINOMA; LUNG CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; TUMOR GROWTH;

EID: 0029800935     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00210787     Document Type: Article

References (37)

1. Garfinkel L, Silverberg E: Lung cancer and smoking trends in the United States over the past 25 years. Cancer-A Cancer J Clinicians 41:137-145, 1991
2. Dodds L, Davis S, Polissar L: A population-based study of lung cancer incidence trends by histological type, 1974-1981. J Natl Cancer Inst 76:21-29, 1986
3. Taylor CW, Crowley J, Williamson SK, Miller TP, Taylor SA, Giri TO, Stephens RL, Livingston RB: Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J Clin Oncol 8:1811-1817, 1990
4. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK: Cancer statistics reviewed 1973-1988, National Cancer Institute, NIH Publication 91-2789, Bethesda, MD, 1991
5. Ihde DC: Chemotherapy of lung cancer. New Engl J Med 27:1434-1441, 1992
6. Sorenson JB, Clerici M, Hanson HH: Single-agent chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 21:89-102, 1988
7. Sorenson JB, Hanson HH: Combination chemotherapy for advanced carcinoma of the lung. Cancer Chemother Pharmacol 21:103-116, 1988
8. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WI, Perry MC, Carey RW, Frei EF, Green MR: A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
9. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tolmey DC, Harris J, Comis R: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
10. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Nelson DI, Clark DC, Feld R, Arnold AN: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter random trial. J Clin Oncol 6:633-641, 1988
11. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
12. Livingston RB: Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience. Semin Oncol 15:S37-S41, 1988
13. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams BL, Bernard JP: Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342:19-21, 1993
14. Ramachandran C, Sauertegit A, Sridhar KS, Thurer RJ, Krishan A: MDR-1 gene expression, anthracycline retention, and cytotoxicity in human-tumor cells from refractory patients. Cancer Chemother Pharmacol 31:431-441, 1993
15. Kelner MJ, McMorris TC, Beck WT, Zamora JM, Taetle R: Preclinical evaluation of Illudins as anticancer agents. Cancer Res 47:3186-3189, 1987
16. Kelner MJ, McMorris TC, Taetle R: Preclinical evaluation of Illudins as anti-cancer agents. Basis for selective cytotoxicity. J Natl Cancer Inst 82:156-165, 1990
17. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MM, Taetle R: Structure activity-relationships of Illudins: analogs with improved therapeutic index. J Org Chem 57:176-183, 1992
18. McMorris TC, Kelner MJ, Wang W, Moon S, Taetle R: On the mechanism of toxicity of Illudins. Chem Res Toxicol 3:574-579, 1990
19. McMorris TC, Kelner MJ, Chadha RK, Siegel JS, Moon S, Moya MM: Structure and reactivity of Illudins. Tetrahydron 45:5533-5540, 1989
20. Kelner MJ, McMorris TC, Taetle R: In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res 15:873-878, 1995
21. Kelner MJ, McMorris TC, Estes L, Rutherford M, Montoya M, Goldstein J, Samson K, Starr R, Taetle R: Characterization of Illudin S sensitivity in DNA repair deficient Chinese hamster cells: unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 48:403-409, 1994
22. Kelner MJ, McMorris TC, Estes L, Starr R, Samson K, Varki N, Taetle R: Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res 15:867-872, 1995
23. Varki NM, Roome L, Sparks RS, Miller JE: Microscopic metastases of human lung carcinoma in athymic nude mice: isolation of a metastatic variant. Int J Cancer 40:46-52, 1987
24. Varki NM, Tseng A, Bu TP, Estes LA: Cloned low metastatic variance from human lung carcinoma metastases. Anticancer Res 10:637-744, 1990
25. Collins SJ, Gallo RC, Gallagher RE: Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270:347-349, 1977
26. Leonard JE, Taetle R, To D, Rhyner K: Preclinical studies on the use of selective antibody ricin conjugated in autologous bone marrow transplantation. Blood 65:1149-1157, 1985
27. McMorris TC, Anchel M: Fungal metabolites. The structures of the novel sesquiterpenes illudin-A and -M. J Am Chem Soc 87:1594-1600, 1965
28. Anchel M, McMorris TC, Singh P: The biogenesis of illudins S and M in Clitocybe illudens. Phytochemistry 9:2339-2343, 1970
29. McMorris TC, Kelner MJ, Wang W, Diaz MA, Estes LA, Taetle R: Acylfulvenes, a new class of potent antitumor agents. Experientia. In press
30. Taetle R, Rosen F, Abramson I, Benditti J, Howell S: Use of nude mouse xenografts as preclinical drug screen: in vivo activity of established chemotherapeutic agents against melanomas and ovarian carcinoma xenografts. Cancer Treat Rep 71:297-304, 1987
31. Altman DG: Practical Statistics for Medical Research. Chapman & Hall, New York, NY, 1991, pp 355-394
32. Brandsteterova E, Kelner MJ, McMorris TC, Estes L, Bagnell R, Montoya M: HPLC determination of a new anticancer agent (acylfulvene) in serum. Neoplasma 39:369-373, 1992
33. Brandsteterova E, Kelner MJ, McMorris TC, Wang W, Bagnell R: HPLC analysis of novel anticancer agents - Illudins and their analogs. J Liquid Chromatography 16:115-125, 1993
34. Kelner MJ, McMorris TC, Estes L, Starr RJ, Rutherford M, Montoya M, Samson KM, Taetle R: Efficacy of Acylfulvene Illudin analogs against a metastatic lung carcinoma MV522 nonresponsive to traditional anticancer agents. Cancer Res 55:4936-4940, 1995
35. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P: Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 17:137-142, 1986
36. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MA, Taetle R: Structure-activity relationships of Illudins: analogs with improved therapeutic index. J Org Chem 57:6876-6883, 1992
37. Sheperd FA: Treatment of advanced non-small cell lung cancer. Semin Oncol 21 (suppl 7):7-18, 1994